[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epilepsy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epilepsy":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,225,0,25,[9,45,74,100,119,151,180,208,239,263,292,317,346,368,390,410,432,451,467,484,508,531,554,576,597],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053675","risk-prevention-program-and-therapeutic-patient-education-program-of-patients-with-uncontrolled-epilepsy-100053675",false,"NCT06202196","Risk Prevention Program and Therapeutic Patient Education Program of Patients With Uncontrolled Epilepsy","Evaluate the Impact of a Specific Risk Prevention Program Associated With a Therapeutic Patient Education Program on the Risk Behaviors of Adult Patients With Uncontrolled Epilepsy.","EPI-RISK","Inclusion Criteria:\n\n* Patient between 18 and 60 years old\n* Patient with poorly controlled epilepsy (persistence of seizures evolving for more than a year despite proper treatment) or patient seizure-free for over a year but for whom therapeutic patient education (TPE) would be beneficial according to the investigator..\n* Patient agreeing to participate in a therapeutic education program (TPE)\n\nExclusion Criteria:\n\n* Epileptic patient who has already benefited from a TPE epilepsy program\n* Patients with major cognitive impairment\n* Patient under guardianship or legal protection (safeguard of justice)\n* Pregnant or breast-feeding women\n* Failure to obtain written informed consent after a reflection period\n* Patient who for geographical, social or psychological reasons could not participate in the research\n* Any situation that, in the opinion of the investigator, could present risks to the patient and to the research\n* Participation in another therapeutic research\n* Subjects not covered by public health insurance","ALL","18 Years","60 Years",{"count":22,"type":23},74,"ESTIMATED","INTERVENTIONAL",[26],"NA","Pilot, controled, randomized study aiming to evaluate a plan for the prevention of risks related to epilepsy, 3 months after the last therapeutic patient education session. Two groups of patients will be compared: group \"intervention\" (consultation with the neurologist then a psychologist followed by a session dedicated to risk prevention (\"Recognize and Manage risks\") integrated into usual Therapeutic Patient Education (TPE) versus \"control\" group (usual consultations with the neurologist and usual TPE).\n\n37 subjects per group will be included in this study.",[29],"Epilepsy",[29,31],"Therapeutic Patient Education","RECRUITING","2026-07-09",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2024-04-16",{"date":40,"type":23},"2028-04-16",{"name":42,"class":43},"University Hospital, Montpellier","OTHER",2,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":51,"targetDuration":4,"studyType":24,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100249911","phase-1-investigation-of-blood-brain-barrier-breakdown-using-manganese-magnetic-resonance-imaging-in-drug-resistant-epilepsy-100249911","NCT02531880","Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy","* INCLUSION CRITERIA:\n* Age 18-60.\n* Able to give written informed consent directly.\n* Drug resistant epilepsy participants will be defined as having clinically documented seizures with consistent EEG evidence as defined by the 1981 International Classification of Epileptic Seizures, refractory to standard anti-seizure treatment for at least one year prior to enrolling in this study and with an average of at least one seizure per month. This criterion will be established by preliminary screening NINDS Epilepsy Service under protocol 18-N-0066. Seizure focus localization will be determined by standard clinical, neurophysiologic, and imaging studies. Prior or concurrent enrollment in 18-N-0066 is required.\n\nEXCLUSION CRITERIA:\n\nGeneral exclusions:\n\n* Patients with epilepsy who are not surgical candidates\n* Significant structural brain abnormality such as a brain tumor, stroke, brain damage from head trauma or blood vessel abnormalities, on the baseline MRI scan.\n* Positive test for HIV\n* Pregnancy or breast-feeding\n* Claustrophobia to a degree that the subject would feel uncomfortable in the MRI machine.\n* Cannot lie on their back for at least two hours.\n* Risk for MRI scan, (e.g., any non-organic implant or other device such as a cardiac pacemaker or infusion pump or other metallic implants, objects or body piercings that cannot be removed, or history of being a welder or metal worker due to small metal fragments in the eye)\n* Unwilling to allow sharing and\u002For use in future studies of coded data that are collected for this study\n\nMEMRI component specific exclusions (applicable only to patients participating in this arm of the study):\n\n* History of post-ictal psychosis or post-ictal aggression\n* Planning to get pregnant in the next 2 months\n* History of clinically significant liver or kidney disease that could potentially increase the risk of CNS damage due to manganese exposure\n* A history of drug or alcohol abuse\u002Fdependence (subjects scoring 8 or higher on the AUDIT scale)\n* Screening lab abnormalities demonstrating values more than 2 times the upper limit of normal for AST, ALT, bilirubin, alkaline phosphatase, BUN, creatinine\n* Previous presumed occupational exposure to manganese (i.e., having worked in a mine, foundry, smelter, dry cell battery manufacturing facility, or agriculture)\n* Allergy to manganese\n* On-going treatment with calcium-channel blocker\n* Iron-deficiency anemia\n* Personal history of Parkinson s Disease or Parkinsonism or presence of this disease in a 1st degree relative\n\nGadolinium enhanced MRI component specific exclusions (applicable only to patients participating in this arm of the study):\n\n* Estimated GFR \\\u003C60, tested within 1 week of scan\n* Allergy to gadolinium\n\nOf note, patients who are ineligible for one arm of the study may still be eligible for and participate in the other arm of the study.",{"count":52,"type":23},40,[54],"PHASE1","Background:\n\n\\- The blood-brain barrier separates the brain from the rest of the body. Epilepsy is a neurological disease that causes seizures. It can affect this barrier. Researchers think a contrast agent called mangafodipir might be better able to show areas of the brain that epilepsy affects.\n\nObjective:\n\n\\- To see if mangafodipir is well tolerated and safe. To see if magnetic resonance imaging (MRI) using either mangafodipir or gadolinium can show areas of blood-brain barrier breakdown in people with epilepsy.\n\nEligibility:\n\n* People ages 18-60 who:\n* Have epilepsy not controlled by drugs\n* Prior or concurrent enrollment in 18-N-0066 is required\n\nDesign:\n\n* Participants will be screened with:\n* Medical history\n* Physical exam\n* Blood and urine tests\n* Participants will have up to 6 visits in 1-3 months. One visit is an inpatient stay lasting 2-10 days. Visits may include:\n* Video-EEG monitoring for participants with epilepsy\n* An IV catheter put in place: a needle guides a thin plastic tube into an arm vein.\n* Getting mangafodipir through the IV.\n* Getting gadolinium through the IV.\n* Up to 6 MRI scans over a 10-day period: a magnetic field and radio waves take pictures of the brain. Participants lie on a table that slides into a metal cylinder. They are in the cylinder for 45-90 minutes, lying still for up to 10 minutes at a time. The scanner makes loud knocking sounds. Participants will get earplugs.\n* A final MRI at least 2 weeks after receiving mangafodipir....",[29],[58,59,60,61,62],"MRI","Manganese Enhanced MRI","Seizure Disorder","Seizures","Epileptic Focus","2026-07-01",{"date":65,"type":36},"2026-07-02",{"date":67,"type":36},"2024-11-19",{"date":69,"type":23},"2030-07-01",{"name":71,"class":72},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":73},"100632997","lilys-grace-temporal-interference-100632997","NCT07520955","Lily's Grace Temporal Interference","Using Temporal Interference to Non-Invasively Enhance Sleep Homeostasis in Patients With Epilepsy","SLEEP-TIES","Inclusion Criteria:\n\n* English-speaking (able to provide consent and complete questionnaires)\n* Citizen or holding permanent resident status\n* History of refractory epilepsy with intractable seizures and\u002For cognitive decline\n\nExclusion Criteria:\n\n* Any current or past history of neurological disorders or acquired neurological disease other than epilepsy (e.g. stroke, traumatic brain injury), including intracranial lesions\n* Current history of poorly controlled headaches including intractable or poorly controlled migraines\n* Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* Possible pregnancy or plan to become pregnant in the next 6 months\n* Any metal in the head\n* Any metal in the body\n* Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator) unless otherwise approved by the responsible MD\n* Dental implants\n* Permanent retainers\n* Claustrophobia (a fear of small or closed places)\n* Back problems that would prevent lying flat for several hours\n* Regular night-shift work (second or third shift)","75 Years",{"count":84,"type":23},24,[26],"This study is to evaluate the effectiveness of targeted Transcranial Electrical Stimulation with Temporal Interference (TES-TI) interventions to boost Non-Rapid Eye Movement (NREM) sleep, decrease seizures and promote emotional health in patients with epilepsy. Up to 24 participants (8 control participants for technical optimization prior to recruitment and 16 patients with epilepsy) will be enrolled and can expect to be on study for up to 24 months.",[29],[89,90],"seizures","non rapid eye movement sleep","NOT_YET_RECRUITING","2026-06-29",{"date":63,"type":36},{"date":95,"type":23},"2026-07",{"date":97,"type":23},"2028-04",{"name":99,"class":43},"University of Wisconsin, Madison",{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":24,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":73},"100591082","effects-of-social-feedback-on-intracranial-eeg-100591082","NCT06975800","Effects of Social Feedback on Intracranial EEG","Inclusion Criteria:\n\n* Patients must be between 18-65 years of age.\n* Patients must have a diagnosis of refractory epilepsy undergoing intracranial EEG recording for clinical purposes.\n* Patients with a legal guardian will be considered for participation if they are interested and, in the judgment of the research team, they are capable of performing the cognitive tasks required of the study. In those instances, the patient and their legal guardian will both participate in the informed consent process, with the legal guardian signing the consent form.\n\nExclusion Criteria:\n\n* Patient has additional neurological condition (such as stroke or dementia) or a psychiatric condition (such as active psychosis or suicidal ideation) and are deemed inappropriate for the study.\n* Patients are not able to provide informed consent for any reason (e.g. encephalopathic, experiencing a seizure).","65 Years",{"count":84,"type":23},[26],"This study aims to assess the impact of social influence on direct neural recordings in human patients undergoing surgical treatment of epilepsy. 24 patients recruited from the Epilepsy Center at Dartmouth Health Medical Center (DHMC) will undergo electrode implantation throughout the brain to localize epileptogenic zones. Patients will be asked to rate their provider's warmth, competence, and other, similar traits associated with care-competency. They will then complete the picture-induced fear and math portions of the multimodal negative affect task (MNAT) during which iEEG is recorded.",[111,29],"Social Influence",{"date":63,"type":36},{"date":114,"type":36},"2023-04-06",{"date":116,"type":23},"2028-02-28",{"name":118,"class":43},"Trustees of Dartmouth College",{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":18,"minAge":127,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":24,"phases":130,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100645336","phase-2-a-phase-2-study-of-the-safety-and-efficacy-of-av078-in-participants-with-tuberous-sclerosis-complex-tsc-refractory-epilepsy-100645336","NCT07680322","A Phase 2 Study of the Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy","A Parallel-Group, Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of the Safety and Efficacy of Oral AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy","RESTOR-1","Key Inclusion Criteria:\n\n* Participants aged 12 years and above.\n* Diagnosis of TSC based on International TSC Consensus Group criteria.\n* History of failure to adequately control seizures despite having been treated by two or more regimens of anti-seizure medications (ASMs).\n* Receiving a stable dose of ASMs for at least 4 weeks at the start of the Screening Period and for the duration of the study.\n\nKey Exclusion Criteria:\n\n* History of any infection requiring use of antibiotics within the last four weeks.\n* Current or history of any clinically significant mental or physical illness or condition other than TSC that the Investigator believes would create significant risk for participation in the study.\n* Recent epilepsy surgery\u002Fmajor surgery or planned surgery during the study.\n* Treatment with medicines which act in a similar way.\n* Treatment with medicines that suppress the immune system.\n* Treatment with medicines that may significantly affect the way the body handles the study drug.","12 Years",{"count":129,"type":23},42,[131],"PHASE2","This Phase 2, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and efficacy of oral AV078 in participants with refractory epilepsy due to tuberous sclerosis complex (TSC). Approximately 42 participants will be randomized in a 5:1 ratio to receive AV078 or placebo.\n\nThe study will include a Screening Period collecting 4 weeks of pre-treatment Baseline data on seizure frequency, and progress to a 12-week Treatment Period, followed by an in person final follow-up visit approximately 2 weeks after the last dose.",[134,29],"Tuberous Sclerosis Complex",[136,137,138,61,139,140,141],"Tuberous Sclerosis Complex (TSC)","Refractory Epilepsy","Drug-Resistant Epilepsy","mTORC1 Inhibitor","AV078","mTOR Pathway","2026-06-25",{"date":65,"type":36},{"date":145,"type":23},"2026-09-01",{"date":147,"type":23},"2027-12-21",{"name":149,"class":150},"Aeovian Pharmaceuticals, Inc.","INDUSTRY",{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":18,"minAge":158,"maxAge":106,"enrollmentInfo":159,"targetDuration":4,"studyType":24,"phases":160,"briefSummary":161,"conditions":162,"keywords":168,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":73},"100645320","non-invasive-low-intensity-focused-ultrasound-stimulation-for-drug-resistant-epilepsy-100645320","NCT07680842","Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy","Pilot Study of Non-Invasive Low Intensity Focused Ultrasound as an Adjunctive Treatment for Drug-Resistant Epilepsy","Inclusion Criteria\n\n* Male or female between 21 and 65 years of age at screening\n* Clinical diagnosis of drug-resistant epilepsy with on average, 4 or more seizures per month.\n* Able to provide informed consent (or assent when applicable) by the subject or subject's legal representative.\n* Be willing to undergo a brain MRI.\n* Be able and willing to wear a headband during the treatment duration.\n* Be able to complete scheduled visits and daily seizure logs.\n\nExclusion Criteria\n\n* Has a craniotomy or pathologic intracranial lesion (e.g. vascular malformations) in the trajectory of the focused ultrasound beam.\n* Pregnant, breastfeeding, is attempting pregnancy, or unwilling to practice birth control during participation in the study.\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n* Has any unstable medical or psychiatric disease.\n* Any contraindications for completing a brain MRI scan.\n* Has evidence of any other clinically relevant neurological disorder at the time of screening, including Alzheimer's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis.","21 Years",{"count":52,"type":23},[26],"The goal of this study is to investigate the effects of a non-invasive, low intensity focused ultrasound (LIFU) stimulation on seizure frequency and the epileptogenic network in drug-resistant epilepsy. LIFU uses focused sound waves to modulate deep brain regions and to enable changes in brain network activity. Encephalography (EEG) and behavioral tasks will also be used to study how LIFU affects brain activity.",[138,29,163,164,165,166,167],"Epilepsy (Treatment Refractory)","Epilepsy Comorbidities","Epilepsy, Drug Resistant","Epilepsy, Generalized","Epilepsy, Focal",[61,138,29,169,170,171,172],"Transcranial Ultrasound Stimulation","Focused ultrasound Stimulation","Electroencephalography (EEG)","Low Intensity Focused ultrasound (LIFU)",{"date":65,"type":36},{"date":175,"type":36},"2025-07-09",{"date":177,"type":23},"2027-06-01",{"name":179,"class":43},"University of California, San Francisco",{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":82,"enrollmentInfo":188,"targetDuration":4,"studyType":24,"phases":190,"briefSummary":192,"conditions":193,"keywords":196,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":207},"100643647","phase-3-study-evaluating-the-efficacy-and-safety-of-rap-219-in-adult-participants-with-focal-seizures-100643647","NCT07594119","Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures","A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures","FOCUS 2","Inclusion Criteria:\n\n1. Age 18 - 75\n2. BMI 18-45 kg\u002Fm2\n3. Diagnosis of focal epilepsy for ≥24 months prior to Visit 1\n4. Report from at least 1 brain MRI or CT scan and 1 EEG study, each completed within 10 years prior to Visit 1, consistent with focal epilepsy diagnosis\n5. Concomitant use of between 1 and 3, inclusive, antiseizure medication(s) ASM(s) as maintenance, not including rescue or pro re nata (PRN) ASMs\n6. Ability to keep accurate daily focal seizure records using an e-diary\n\nExclusion Criteria:\n\n1. Known hypersensitivity or prior exposure to RAP-219.\n2. Unstable or uncontrolled serious medical, neurologic (other than focal epilepsy), or psychiatric condition that is ongoing or considered likely to recur\n3. Anticipated need for surgery during the study period\n4. Medical history of any of the following:\n\n   1. generalized epilepsy\n   2. focal preserved consciousness without observable manifestations (also known as focal aware nonmotor) as the participant's only seizure type\n   3. psychogenic nonepileptic seizure (PNES)\n   4. status epilepticus or seizure clusters (when individual seizures cannot be counted) within 12 months prior to Visit 1 (Day -56).\n   5. epilepsy surgery within 12 months prior to Visit 1 (Day -56).\n5. Participation in another clinical study of an investigational product within 12 weeks or 5 half-lives of this other investigational product",{"count":189,"type":23},312,[191],"PHASE3","This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.",[194,29,195],"Focal Seizure","Focal Epilepsy",[197,198],"Focal Preserved Consciousness","Focal Impaired Consciousness","2026-06-24",{"date":142,"type":36},{"date":202,"type":23},"2026-06",{"date":204,"type":23},"2029-09",{"name":206,"class":150},"Rapport Therapeutics Inc.",3,{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":18,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":219,"phases":4,"briefSummary":220,"conditions":221,"keywords":227,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":73},"100517564","mehmo-natural-history-and-biomarkers-100517564","NCT06019182","MEHMO Natural History and Biomarkers","Investigations of Individuals With MEHMO Syndrome or eIF2-Pathway Related Conditions","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet the following criteria:\n\nBe \\>= 1-week of age if affected, or \\>=1-month of age if unaffected.\n\nFor Screening:\n\n1. Have a combination of signs\u002Fsymptoms suggestive of MEHMO syndrome,\n\n   AND\n\n   no or inconclusive molecular testing.\n\n   OR\n2. Be a relative of an individual with MEHMO syndrome\u002FeIF2-related condition and whose genetic may be informative for research.\n\nFor Main Study:\n\n1. Have a combination of signs\u002Fsymptoms suggestive of MEHMO syndrome,\n\n   AND\n\n   disease-associated variant(s) or variant(s) of uncertain significance in one of the eIF2-pathway related genes\n\n   OR\n2. Be a relative of an individual with MEHMO syndrome\u002FeIF2-related condition, AND a carrier of the pathogenic or likely pathogenic variant.\n\n   OR\n3. Be a non-affected, non-carrier family member of an individual with MEHMO syndrome or an eIF2-pathway related condition.\n\nEXCLUSION CRITERIA:\n\nAny individual who, in the opinion of the Investigators, is unable to comply with the protocol or have medical conditions that would potentially increase the risk of participation will be excluded from participation in this study.","1 Week","100 Years",{"count":218,"type":23},150,"OBSERVATIONAL","This observational natural history study will follow individuals with MEHMO (Mental disability, Epileptic seizure, Hypopituitarism\u002FHypogenitalism, Microcephaly, Obesity) syndrome or an eIF2-pathway related disorder, who have symptoms such as intellectual delay, seizures, abnormal hormone and blood sugar levels, and decreased motor skills.\n\nNo current treatment for these conditions is available. A major impediment to the testing of potential therapeutic interventions is the lack of well-defined outcome measures. This protocol seeks to identify biochemical and clinical markers to monitor disease progression, and better understand the natural history of these conditions.\n\nAny person diagnosed with MEHMO syndrome or related conditions, who can travel to the NIH Clinical Center can participate in this study.\n\nThe study involves:\n\n* General health assessment and evaluation\n* Imaging studies\n* Laboratory tests\n* Collection of blood, urine, spinal fluid, skin biopsy.",[222,29,223,224,225,226],"Intellectual Disability","Hypogonadisms","Microcephaly","Nervous System Malformations","Obesity",[228,229,230,231],"MEHMO","X-linked MEHMO Syndrome","eIF2-Pathway Related Conditions","EIF2S3",{"date":142,"type":36},{"date":234,"type":36},"2023-10-23",{"date":236,"type":23},"2053-09-01",{"name":238,"class":72},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":245,"sex":18,"minAge":246,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":219,"phases":4,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":73},"100217448","noninvasive-pre-surgical-evaluation-of-patients-with-focal-epilepsy-and-establishment-of-a-normative-imaging-database-100217448","NCT02107989","Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database","* INCLUSION CRITERIA FOR PATIENTS:\n* Age 8 and older\n* Evaluated or under evaluation for epilepsy surgery under protocol 18-N-0066,11-N-0051 or 16-N-0041\n* Documentation of focal epilepsy based on MRI, EEG and\u002For ictal semiology\n* Ability to give informed consent, have or be able to assign a legally authorized representative able to give consent (for adults without consent capacity), or parent\u002Fguardian able to provide informed consent (for a child).\n\nINCLUSION CRITERIA FOR PATIENTS SOLELY CONTRIBUTING DATA:\n\n* Had epilepsy surgery with presurgical evaluation under 18-N-0066\n* Age 8 and up at the time of epilepsy surgery evaluation\n* Had a preoperative structural brain MRI of the type used in this protocol\n\nINCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:\n\n* Age 8 and older\n* Ability to give informed consent or have a parent\u002Fguardian able to provide informed consent if a child.\n* Ability to cooperate with MRI scanning without anesthesia\n\nEXCLUSION CRITERIA FOR PATIENTS:\n\n* Contraindications to MRI or MEG studies (such as pacemakers, cochlear implants, shrapnel, permanent eyeliner)\n* Claustrophobia or anxiety disorders exacerbated by the MRI scanner\n* Pregnancy. All females of childbearing potential must have a negative pregnancy test prior to MRI scanning\n\nEXCLUSION CRITERIA FOR PATIENTS SOLELY CONTRIBUTING DATA:\n\n-Not able or willing to give consent or do not have an appropriate surrogate who can provide consent\n\nEXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:\n\n* Contraindications to MRI or MEG studies (such as pacemakers, cochlear implants, shrapnel, permanent eyeliner)\n* Claustrophobia or anxiety disorders exacerbated by the MRI scanner\n* Significant medical conditions that may affect the central nervous system, such as psychiatric disorders (such as mood disorders, psychotic disorders, substance abuse or dependence), significant neurologic disorders (such as brain injury, neurodegenerative disorders, multiple sclerosis, stroke, movement disorders, epilepsy), or active systemic disease that may affect the central nervous system (such as uncontrolled hypertension, autoimmune disorders or other inflammatory disorders, neoplastic disease)\n* Use of centrally acting medications in the past 6 weeks, such as benzodiazepines, barbiturates, antidepressants, beta-blockers, and drugs for treating epilepsy or migraine\n* Pregnancy. All females of childbearing potential must have a negative pregnancy test prior to MRI scanning",true,"8 Years","120 Years",{"count":249,"type":23},700,"Objectives:\n\nThe overall study objective is to compare the sensitivities and specificities of morphometric analysis techniques using structural MRI images based on pre- and postsurgical localization of epileptic foci in patients undergoing presurgical evaluation for medically refractory epilepsy. To carry out these analyses, we aim to establish an age-stratified normative imaging database using healthy volunteers. Additional objectives are to identify abnormal networks in these patients using resting state fMRI\u002FEEG and MEG\u002FEEG, and to use language and memory fMRI tasks to examine the effects of epileptogenic zones and surgery on cognitive function and the networks associated with these functions.\n\nStudy population:\n\n300 adults and children (age 8 and older) with uncontrolled focal epilepsy, and 200 age-stratified healthy volunteers.\n\nDesign: A retrospective and prospective natural history study. Research procedures for patients in this study include neuropsychological testing and 1-4 MRI sessions during presurgical evaluation and an additional 1-3 MRI sessions and neuropsychological testing approximately 12 months post-operatively. Research testing (such as research neuropsychological tests or MRI scanning sequences) will be done during a visit for clinical testing whenever possible, likely reducing the number of required visits. Patients will also have optional MEG and 7T structural imaging. Data will also be obtained from patients who have already undergone epilepsy surgery if they had procedures as outlined in the protocol and are willing to share the data. Healthy volunteers will receive a subset of the pre-operative procedures for patients, requiring at least 3 visits. In order to ensure adequate data acquisition, subjects may be re-scanned up to three times for the portions of the study in which they participated, possibly requiring additional visits.\n\nOutcome measures:\n\nThe main outcomes will be establishment of normative values for morphometric analysis methods in age-stratified normal controls, and comparison of the sensitivity and specificity of these measures to pre- and postsurgical localization of the epileptogenic zone. Secondary outcome measures will include determination of the sensitivity and specificity of source localization using MEG\u002FEEG and resting state fMRI\u002FEEG, and to evaluate changes in activation during rest, as well as language and memory fMRI tasks in patients pre- and postsurgically, to examine the effects of epileptogenic zones and surgery on cognitive function and the networks underlying these functions.",[29],[29,58,253,254,255],"fMRI","MEG","Natural History","2026-06-23",{"date":199,"type":36},{"date":259,"type":36},"2014-03-11",{"date":261,"type":23},"2028-03-30",{"name":71,"class":72},{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":18,"minAge":270,"maxAge":19,"enrollmentInfo":271,"targetDuration":4,"studyType":24,"phases":273,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":73},"100643929","phase-3-cannabidiol-as-add-on-therapy-for-children-with-refractory-epilepsy-cbd-un1que-a-high-quality-individualized-approach-a-series-of-n-of-1-trials-100643929","NCT07668856","Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials","CBD-uN1que","Inclusion Criteria:\n\n* Minimum age of 1 year old and maximum age of 18 years old.\n* Confirmed diagnosis of refractory epilepsy according to ILAE criteria\n* At least 4 countable seizures (not all in one week) of epileptic origin, during the 4-week baseline period while receiving care as usual.\n* All medication doses or other interventions for epilepsy must have been stable for one month prior to screening and the participants\u002Fparents and treating physicians are willing to maintain the current treatment regimen throughout the trial.\n* Informed consent\u002F of legal representative\u002F parents.\n* Presence of a consistently available patient caregiver for proxy-reports.\n\nExclusion Criteria:\n\n* Any known or suspected hypersensitivity to cannabinoids or any of the excipients of the Investigational Medicinal Product (cannabis extract and refined peanut oil, generally safe for patients with peanut allergy)\n* History or current signs of significantly impaired liver function, such as bilirubin level ≥ 2 x upper limit of normal, or presence of liver damage as indicated by levels of alanine aminotransferase and\u002For aspartate aminotransferase ≥ 3 x upper limit.\n* Pregnancy, breastfeeding, or intention to become pregnant throughout the trial or within 3 months of completing treatment\n* Cardiac disease including: Structural heart disease with hemodynamic significance, heart failure, ischemic heart disease, Brugada syndrome, long-QT syndrome, cardiac arrythmia\n* Glaucoma\n* Ongoing evaluation for epilepsy surgery\n* Implementation of vagal nerve stimulation within 3 months prior to screening and unwillingness to delay inclusion until stable settings of vagal nerve stimulation are reached\n* Starting a ketogenic diet within 3 months prior to screening and unwillingness to delay inclusion until a stable ketogenic diet is reached\n* Unstable medical condition, other than refractory epilepsy, that is of significant influence on participation in the trial; significance to be determined with the treating physician\u002Fpediatric neurologist\n* History of recreational or medicinal cannabis use, or cannabinoid-based medications, within three months prior to screening and the patient is unwilling to abstain for the duration of the study\n* Planned intervention under general anesthesia interfering with the baseline period; or any planned major surgery within the duration of the trial\n* Expected inability to undergo blood sampling due to anxiety or resistance\n* Use of clobazam dosage of \\> 0,5 mg\u002Fkg\u002Fday in the last month","1 Year",{"count":272,"type":23},50,[191],"The goal of this clinical trial is to learn if cannabidiol (\"CBD-oil\") works to treat severe epilepsy in children. It will also learn about the safety of cannabidiol. The main questions it aims to answer are:\n\n* Does cannabidiol lower the number of seizure in children with severe epilepsy?\n* Does cannabidiol effect other outcomes such as behaviour, sleep, communication, activities?\n* What medical problems do participants have when taking cannabidiol?\n\nResearchers will compare cannabidiol to a placebo (a look-alike oil that contains no cannabidiol) to see if drug cannabidiol works to treat severe epilepsy. All participants will receive both the cannabidiol and the placebo during different periods. At the end of the trial, we will evaluate for each patient seperately, whether seizures were less or more frequent during cannabidiol periods or placebo periods, to see what works best for every patient seperately.\n\nParticipants will:\n\n* Register their seizures in a digital application during 4 to 6 periods. During these periods, CBD oil of placebo will be provided\n* Take CBD oil during 2 to 3 periods. One period will last around 7 weeks.\n* Also take placebo oil during the other 2 to 3 periods\n* Have a blood test every 7 weeks to monitor for safety and possible adverse effects\n* Visit the clinic once every 15 weeks for checkups and tests\n* Fill in questionnaires about quality of life, functioning, sleep, behaviour, epilepsy severity every 7 weeks.",[276,137,29],"Refractory Epilepsy in Children",[278,279,280,281,282,283],"Refractory epilepsy","rare diseases","Cannabidiol.","bedrolite","n-of-1 trial","medicinal cannabis","2026-06-19",{"date":142,"type":36},{"date":287,"type":36},"2025-02-06",{"date":289,"type":23},"2027-12",{"name":291,"class":43},"UMC Utrecht",{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":106,"enrollmentInfo":300,"targetDuration":4,"studyType":219,"phases":4,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":310,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":73},"100590478","sleep-and-rehearsal-driven-memory-in-epilepsy-100590478","NCT06967935","Sleep and Rehearsal-Driven Memory in Epilepsy","Rehearsal-Induced Memory Consolidation and Its Modulation by Sleep in People With Epilepsy","CORESOM-EPI","Inclusion Criteria:\n\n* Patient with epilepsy (any type of epilepsy)\n* Hospitalized for video-EEG recording lasting at least 4 days\n* Aged 18-65 years\n\nExclusion Criteria:\n\n* Major cognitive impairment other than memory deficit\n* Refusal to participate\n* Pregnant women, women in labor or nursing mothers\n* Persons deprived of their liberty by judicial or administrative decision\n* Persons under psychiatric care\n* Persons admitted to a health or social institution for purposes other than research\n* Adults under legal protection (guardianship, curatorship)",{"count":301,"type":23},20,"Memory consolidation transforms unstable memory traces into lasting representations, a process enhanced by both sleep and rehearsal during learning. Rehearsal is thought to accelerate consolidation by inducing memory reactivations that resemble those occurring during sleep. However, the respective mechanisms of sleep- and rehearsal-induced consolidation-and their potential interactions-remain poorly understood, especially in patients with temporal lobe epilepsy, where rehearsal might help compensate for memory deficits linked to hippocampal dysfunction, and where sleep may exacerbate epileptic activity. The CORESOM-EPI study aims to compare the effects of rehearsal and sleep on memory consolidation in patients undergoing video-EEG monitoring. Participants will learn \"object-place\" associations under two conditions (single versus repeated encoding), with memory tested immediately and again after a 12-hour delay. This delay will either include a full day awake or a night of sleep, allowing direct comparison of sleep- and rehearsal-related consolidation effects. Each participant will perform the task twice, with \"wake\" and \"sleep\" condition, in a balanced order. As a preliminary phase of the CRIMES study (ANR-DFG 2024), CORESOM-EPI will help assess how sleep and rehearsal influence memory consolidation in epilepsy. It will also serve to adapt the behavioral task for clinical use, paving the way for a future intracranial EEG investigations that will explore the neural networks involved and their modulation by epileptic activity.",[29,304],"Memory Consolidation",[29,306,307,308,309],"Memory consolidation","Sleep","Reharsal","Reactivation",{"date":256,"type":36},{"date":312,"type":36},"2025-06-30",{"date":314,"type":23},"2027-07",{"name":316,"class":43},"Hospices Civils de Lyon",{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":24,"phases":327,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":73},"100504886","stimulation-induced-changes-in-fronto-limbic-network-100504886","NCT05854160","Stimulation-Induced Changes in Fronto-Limbic Network","Stimulation-Induced Changes in Fronto-Limbic Connectivity Control Regulation of the Emotional Response to Threat","Stim_Con","Inclusion Criteria:\n\n* 1\\) implantation of sEEG electrodes for SOC epilepsy surgery evaluation\n* 2\\) cognitive ability to perform simple tasks and to understand instructions\n* 3\\) implanted electrodes in the amygdala and medial PFC regions\n* 4\\) competency to understand and sign a written informed consent.\n\nExclusion Criteria:\n\n* 1\\) an inability to complete the task",{"count":326,"type":23},30,[26],"The purpose of this research is to better understand how emotion processing unfolds in the brain using stereoelectroencephalography (sEEG) and direct brain stimulation. This study will use standard behavioral emotion processing tasks combined with neural recording and direct brain stimulation to assess different aspects of emotion processing. Stimulation pulses during pre and post-test periods will assess the effects of stimulation before and after conditioning, the results of which will be combined with results from the activity of each electrode during the emotion tasks to inform us of the nature of emotion processing in the brain and allow us to devise brain modulation protocols in the future.",[29,330],"Mental Disorders",[332,333,334,335,336,337],"epilepsy","comorbid mental health disorders","sEEG","Anxiety","Fronto-limbic network","Pavlovian fear conditioning paradigm","2026-06-18",{"date":256,"type":36},{"date":341,"type":36},"2023-03-01",{"date":343,"type":23},"2027-02-24",{"name":345,"class":43},"University of Alabama at Birmingham",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":24,"phases":356,"briefSummary":357,"conditions":358,"keywords":360,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":73},"100372848","carbon-dioxide-co2-chemosensitivity-and-sudep-100372848","NCT04134754","Carbon Dioxide (CO2) Chemosensitivity and SUDEP","The Role of Central CO2 Chemosensitivity in Postictal Respiratory Depression and SUDEP","Inclusion Criteria:\n\n1. The subject is between 18 and 99 years of age.\n2. Confirmed or suspected epilepsy.\n3. Admission to the EMU for spell characterization (EMU group) or undergoing care in the University of Iowa Health Care Epilepsy Clinic.\n\nExclusion Criteria:\n\n1. History of uncontrolled cardiac, pulmonary, or hepatic disease.\n2. Progressive or uncontrolled neurologic disease unrelated to epilepsy.\n3. Current opioid use.\n4. Women of child-bearing potential who are pregnant or capable of becoming pregnant (e.g. sexual activity within the past 21 days without a highly effective form of birth control or positive urine pregnancy test).\n5. Other comorbid condition that may influence the safety or feasibility of HCVR testing.\n6. Limited decision-making capacity and absence of a qualified representative.","99 Years",{"count":355,"type":23},335,[26],"The purpose of this research study is to better understand what causes Sudden Unexpected Death in Epilepsy (SUDEP). This study will enroll subjects from the University of Iowa Hospitals and Clinics (UIHC) Epilepsy Monitoring Unit (EMU) and Epilepsy Clinics. The investigators will analyze the effects of seizures on breathing, on the cardiovascular system, and on arousal. The investigators are studying these effects because some cases of SUDEP might be due, in part, to an inability to wake up or sense elevated carbon dioxide (CO2) levels when breathing is impaired. Subjects will be followed for ten years after enrollment to monitor their health.",[29,359],"SUDEP",[29],{"date":256,"type":36},{"date":363,"type":36},"2019-12-12",{"date":365,"type":23},"2029-10-01",{"name":367,"class":43},"University of Iowa",{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":18,"minAge":246,"maxAge":353,"enrollmentInfo":374,"targetDuration":4,"studyType":219,"phases":4,"briefSummary":376,"conditions":377,"keywords":380,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":73},"100258134","tumor-related-epilepsy-100258134","NCT02639325","Tumor Related Epilepsy","* INCLUSION CRITERIA:\n\nTo be eligible for entry into the study, a candidate must meet all the following criteria:\n\n* Be 8 years of age or older.\n* Have solitary primary or recurrent brain tumor with associated seizures. Brain tumor may be diagnosed radiologically. Associated seizures are defined as those with activity starting within three months of radiologic diagnosis of the primary or recurrent tumor. In cases when the timing of seizure activity is unclear with respect to the timing of diagnosis, seizures will be considered associated with the tumor if seizure semiology is consistent with that location. Ongoing seizures are not required. Patients can be included if they have had a single previous seizure. Patients who have not experienced seizures after institution of anti-convulsant therapy are not excluded.\n\nEXCLUSION CRITERIA:\n\nCandidates will be excluded if they:\n\n-At the time of enrollment, lack consent capacity due to cognitive impairment that would make them incapable of understanding the explanation of the procedures in this study. Cognitive capacity to consent will be determined at the time of enrollment. Patients with mental disorders or those patients who are cognitively impaired yet still retain consent capacity will not be excluded. Children may be enrolled if there is a parent or guardian able to consent on their behalf.",{"count":375,"type":23},100,"Background:\n\nSome people with brain tumors have seizures related to the tumor. This is called tumor-related epilepsy. Usually brain tumors are treated by removing as much of the brain tumor as possible without causing problems. Researchers think this may improve the outcome for people with brain tumors. It may completely relieve or greatly reduce the number of seizures they have.\n\nObjectives:\n\nTo evaluate people with brain tumors that are associated with seizures and to offer surgical treatment. Also, to study how surgery affects seizures.\n\nEligibility:\n\nPeople age 8 and older who have a brain tumor with associated seizures. They must be willing to have brain surgery to treat their epilepsy.\n\nDesign:\n\nParticipants will be screened with a review of their medical records.\n\nParticipants will have a medical history and physical exam.\n\nParticipants will be admitted to the hospital at NIH. They will have\n\nMedical history\n\nPhysical exam\n\nNeurological exam\n\nTests of memory, attention, and thinking\n\nQuestions about their symptoms and quality of life\n\nBlood drawn\n\nThey may also have:\n\nMRI or CT scan. They will lie on a table that slides in and out of a machine that takes pictures. For part of the MRI, they will get a dye through an intravenous (IV) catheter.\n\nVideo electroencephalography monitoring. Electrodes will be placed on the scalp. The participant s brain waves will be recorded while doing normal activities. Participants will be videotaped.\n\nParticipants will keep a seizure diary before and after surgery.\n\nParticipants will have surgery to remove their brain tumor and the brain area where their seizures start.\n\nThey will stay in the hospital up to a week after surgery.\n\nParticipants have for follow-up visits at NIH.",[29,378,379],"Cancer","Brain Neoplasm",[381,382,60,61,255],"Brain Tumor","Brain Cancer",{"date":384,"type":36},"2026-06-22",{"date":386,"type":36},"2016-01-26",{"date":388,"type":23},"2032-07-01",{"name":71,"class":72},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":219,"phases":4,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":73},"100450036","de-identified-unmh-eeg-corpus-database-creation-with-fully-de-identified-clinical-information-100450036","NCT05140265","De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information","The Creation of a Pilot Database of EEG Recordings and de- Identified Medical Records From Patients Internally Referred Within the UNMH Comprehensive Epilepsy Center","Inclusion Criteria:\n\n* We will screen with UNMH EEG database, Nihon Kohden Neuroworkbench first. After meeting all the inclusion and exclusion criteria, we will access the Cerner Powerchart (UNMH EMR) for the rest of the clinical information.\n* 18 years old or older. If the patient's age is over 89, we will aggregated them to age 90 or older so that the patient cannot be identified. Also, all the EEG data will be de-identified and only show the year of the study performed instead of the exact study date to reduce the risk of identification. Of note, we perform over few thousands of EEG studies per year and it will be almost impossible to identify the patient based on the study year.\n\nExclusion Criteria:\n\n* Children under age of 18 years old will be excluded.\n* Mismatched patients between EEG database and EMR",{"count":398,"type":23},20000,"This proposal outlines the steps required for the creation of a pilot database of EEG recordings and de-identified medical records from patients internally referred within the UNMH Comprehensive Epilepsy Center. The UNMH EEG Corpus would be the first database of its kind. Other public databases contain either patient EEG signals or medical records, but without both kinds of information, it is impossible to relate pre-treatment neurobiomarkers with post-treatment prognosis. The database will also contain information that can improve seizure localization based off of scalp and intracranial EEG, and the requisite data for the creation of algorithms that forecast seizure activity; a development that could ultimately lead to novel responsive neural stimulation procedures that suppress seizures before they begin.",[29,401,61],"Status Epilepticus","2026-06-17",{"date":384,"type":36},{"date":405,"type":36},"2021-10-11",{"date":407,"type":23},"2030-12-31",{"name":409,"class":43},"University of New Mexico",{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":245,"sex":18,"minAge":19,"maxAge":106,"enrollmentInfo":417,"targetDuration":4,"studyType":24,"phases":419,"briefSummary":420,"conditions":421,"keywords":422,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":73},"100644430","cognitive-and-electrophysiological-assessment-of-non-invasive-temporally-interfering-electric-fields-stimulation-tiefs-100644430","NCT07663578","Cognitive and Electrophysiological Assessment of Non-Invasive Temporally-Interfering Electric Fields Stimulation (TIEFS)","TIEFS","Inclusion Criteria:\n\n* Adult patients (age 18-65 years of age) undergoing an intracerebral electrophysiology study for epilepsy pre-surgical evaluation are eligible for inclusion.\n* For healthy control subjects are also eligible for inclusion (Scalp EEG measurements).\n* Participants must be able to sufficiently speak and understand English or Spanish for consent and be able to understand and complete cognitive tasks.\n* All subjects must have the ability to give valid informed consent.\n\nExclusion Criteria:\n\n* No pregnant women will be recruited.\n* People with implanted electrical devices such as Deep Brain Stimulation devices or Pacemakers.\n* No prisoners will be recruited.",{"count":418,"type":23},15,[26],"The goal of this clinical trial is to learn how a non-invasive brain stimulation method called Temporally Interfering Electric Fields Stimulation (TIEFS) affects brain activity and thinking in adults. TIEFS uses electrical currents applied to the scalp to influence brain activity without surgery.\n\nThe main questions this study aims to answer are:\n\n* How does TIEFS change brain signals measured with brain recordings?\n* Does TIEFS affect thinking abilities such as memory, language, movement, or perception?\n* Is TIEFS safe and well tolerated when used in people?\n\nThis study includes two groups of participants. One group includes adults with epilepsy who are already undergoing specialized brain monitoring as part of their medical care. The other group includes healthy adults with no history of seizures.\n\nParticipants will:\n\n* Receive brief sessions of TIEFS using electrodes placed on the scalp\n* Complete computer-based tasks that test memory, attention, language, or movement. Answer questions about how the stimulation feels\n* Have brain activity recorded during the study\n\nEach study visit lasts up to three hours and may occur in one or two sessions. Information from this study may help researchers better understand the human brain and support the development of future non-invasive brain stimulation treatments.",[29],[423],"Brain Stimulation","2026-06-16",{"date":256,"type":36},{"date":427,"type":36},"2025-04-16",{"date":429,"type":23},"2027-04-15",{"name":431,"class":43},"University of California, Davis",{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":439,"targetDuration":4,"studyType":24,"phases":441,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":73},"100515507","readiness-brain-operation-optimization-training-reboot-for-epilepsy-surgery-100515507","NCT05992402","Readiness Brain Operation Optimization Training (ReBOOT) for Epilepsy Surgery","ReBOOT","Inclusion Criteria:\n\n* Adults, aged 18-60 years old, with diagnosed epilepsy who have been confirmed as an appropriate surgical candidate by their epileptologist\n* Able to independently provide informed consent\n* Fluent in English\n* Reading abilities at or above 8th grade level as determined by the Wide Range Achievement Test- 4th Edition (WRAT-4), Reading subtest.\n* Internet access and the ability to participate in online video streaming\n* No history of resective or ablative neurosurgery, but this does not include neuromodulation therapies for epilepsy (e.g., RNS, VNS, DBS)\n* Willing and able to participate in cognitive intervention\n\nExclusion Criteria:\n\n* Any patient that has engaged in any form of cognitive rehabilitation\u002Fintervention within the last 6 months\n* Ongoing litigation related to the cause of epilepsy, unless litigation is related to short term or long-term disability application.\n* Undergoing intensive medical treatment for serious or life-threatening illness (e.g., chemotherapy, etc.) that would impact study participation.\n* Serious psychiatric condition that could interfere with participation, such as schizophrenia, active psychosis, active mania, and current suicidal ideation.\n* Significant hearing and\u002For vision loss that would preclude them from participating in remote cognitive testing and engaging in the cognitive intervention.",{"count":440,"type":23},64,[26],"The goal of this clinical trial is to learn if new educational program prior to epilepsy surgery can either decrease the risk of cognitive decline after surgery or be a help to those patients who experience a decline after undergoing epilepsy surgery.\n\nParticipants will participate in 2 individual virtual sessions and 4 virtual group sessions over the course of 5-6 weeks prior to their epilepsy surgery. They will asked to fill out online surveys and questionnaires at various times throughout the study, up to 12 months after their surgery.\n\nTo see if the educational program works, researchers will compare those participating in the educational program with those that are receiving the standard epilepsy care prior to surgery.",[29],{"date":338,"type":36},{"date":446,"type":36},"2023-12-06",{"date":448,"type":23},"2028-06",{"name":450,"class":43},"Kayela Arrotta",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":457,"targetDuration":4,"studyType":24,"phases":459,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":466,"locationsCount":73},"100512571","cognitive-enhancement-intervention-for-creating-a-healthy-life-lifestyle-interventions-for-epilepsy-100512571","NCT05954182","Cognitive Enhancement Intervention for Creating a Healthy L.I.F.E (Lifestyle Interventions for Epilepsy)","Inclusion Criteria:\n\n* Potential patients will be identified if they have been, or are scheduled to be seen, either in-person or virtually for a clinical visit within the Cleveland Clinic Epilepsy Center\n* Adults, aged 18-60 years old, with diagnosed epilepsy\n* Subjective cognitive difficulties based on patient self-report or objective cognitive deficits as determined by neuropsychological tests\n* Able to independently provide informed consent\n* Fluent in English\n* Reading abilities at or above 8th grade level as determined by the Wide Range Achievement Test- 4th Edition (WRAT-4), Reading subtest\n* Internet access and the ability to participate in online video streaming\n* No history of resective or ablative epilepsy surgery\n* Willing and able to participate in cognitive intervention\n\nExclusion Criteria:\n\n* Patients with a current diagnosis of non-epileptic or psychogenic seizures\n* Any patient that has engaged in any form of cognitive rehabilitation\u002Fintervention within the last 6 months\n* Patients currently enrolled in another interventional study for epilepsy at the time of enrollment\n* Anticipated or scheduled epilepsy surgery within 6 months\n* Pending litigation related to the cause of epilepsy unless litigation is related to disability application\n* Undergoing intensive medical treatment for serious or life-threatening illness (e.g., chemotherapy, etc.) that, in the opinion of the investigator, would impact study participation\n* Serious psychiatric condition that, in the opinion of the investigator, would interfere with participation, such as schizophrenia, active psychosis, active mania, and current suicidal ideation\n* Currently pregnant or less than 6 weeks postpartum\n* Significant hearing and\u002For vision loss that, in the opinion of the investigator would preclude them from participating in remote cognitive testing and engaging in the cognitive intervention\n* Participants who require an LAR or lack capacity to consent for themselves",{"count":458,"type":23},170,[26],"The goal of this clinical trial is to test if cognitive interventions in those with diagnosed epilepsy can help lessen cognitive lapses and improve overall brain health.\n\nParticipants will participate in weekly, virtual group sessions led by a neuropsychologist for 12 weeks. After the 12-week mark, participants will be asked to practice what they learned for 9 more months. Participants will be asked to complete online questionnaires at certain times during the study. Researchers will compare this intervention group to another group that did not get the intervention to see if the intervention improves brain health. Participation in each of these groups will be randomly assigned. Participation in the study will last for one year.",[29],{"date":338,"type":36},{"date":464,"type":36},"2023-09-20",{"date":202,"type":23},{"name":450,"class":43},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":185,"acronym":472,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":82,"enrollmentInfo":473,"targetDuration":4,"studyType":24,"phases":475,"briefSummary":192,"conditions":476,"keywords":477,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":483,"locationsCount":207},"100636299","phase-3-study-evaluating-the-efficacy-and-safety-of-rap-219-in-adult-participants-with-focal-seizures-focus-1-100636299","NCT07563881","Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1","FOCUS 1",{"count":474,"type":23},333,[191],[194,29,195],[197,198],"2026-06-12",{"date":424,"type":36},{"date":481,"type":36},"2026-06-05",{"date":204,"type":23},{"name":206,"class":150},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":245,"sex":491,"minAge":19,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":24,"phases":494,"briefSummary":495,"conditions":496,"keywords":499,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":504,"leadSponsor":506,"locationsCount":73},"100642298","bone-management-in-pregnancy-outcomes-in-epilepsy-100642298","NCT07651709","Bone Management in Pregnancy Outcomes in Epilepsy","Bone Health Management on Pregnancy Outcomes in Women With Epilepsy: Randomized Study","Inclusion Criteria:\n\n* Diagnosis of focal or generalized epilepsy as defined by the International League Against Epilepsy.\n* Women of childbearing age, aged ≥18 years, planning pregnancy or in early pregnancy (≤16 weeks gestation, confirmed by last menstrual period or ultrasound) - single pregnancy.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Pre-existing conditions affecting bone metabolism: primary hyperparathyroidism, Paget's disease, multiple myeloma, chronic kidney disease (eGFR \\\u003C60 mL\u002Fmin), cirrhosis (Child-Pugh B\u002FC), or untreated hyper\u002Fhypothyroidism.\n* History of metabolic complications: hypercalcemia (serum Ca²⁺ \\>10.5 mg\u002FdL), nephrolithiasis, or granulomatous diseases.\n* Recent\u002Fcurrent use of bone-modifying drugs: bisphosphonates, glucocorticoids (≥5 mg\u002Fday prednisone equivalent for \\>1 month), or loop diuretics within the past year.\n* Ultrasound shows fetal malformation.\n* Presence of other severe systemic diseases deemed unsuitable for study participation by the investigator.","FEMALE",{"count":493,"type":23},80,[26],"This study is aimed to evaluate the efficacy of bone health management in improving pregnancy outcomes among WWE, and establish evidence-based vitamin D supplementation strategies for childbearing-age WWE.",[29,497,498],"Pregnant Woman","Bone Health",[332,500],"pregnancy","2026-06-11",{"date":424,"type":36},{"date":202,"type":23},{"date":505,"type":23},"2035-01",{"name":507,"class":43},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":245,"sex":18,"minAge":19,"maxAge":515,"enrollmentInfo":516,"targetDuration":4,"studyType":24,"phases":518,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":530},"100596911","phase-1-dose-escalation-study-to-assess-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-sif001-in-healthy-subjects-and-in-epilepsy-patients-100596911","NCT07051629","Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients","A Phase 1, Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIF001 in Healthy Subjects and in a Patient Cohort With Epilepsy","Inclusion Criteria:\n\n\\-\n\nHealthy Volunteers Only (Stage I and II (Phase 1a and 1b)):\n\n1. Male or female 18 to 55 years of age at the time of signing the informed consent.\n2. In good health as determined by the Investigator, based on medical history and screening evaluations.\n3. Body weight of ≥ 50 kg and BMI within the range 18-30 kg\u002Fm2 (inclusive)\n\n   Patients with Epilepsy Only (Stage II (Phase 1b)):\n4. Male or female 18 to 70 years of age at the time of signing the informed consent.\n5. A clinical diagnosis of focal or generalized epilepsy. Subjects must have motor seizures, with or without impaired awareness.\n6. Has a minimum of 4 seizures per 4-week period while taking 1 to 3 anti-seizure medications\n7. All medications and epilepsy interventions must be stable for 8 weeks before screening and are expected to remain stable during the study\n\n   All Subjects:\n8. Negative serum pregnancy test at screening and urine pregnancy test on Day -1 before starting study treatment in all pre-menopausal women and women \\\u003C 12 months after the onset of menopause.\n9. Female participants of child-bearing potential and male participants must agree to use adequate contraception for the duration of the protocol.\n10. Able to sign informed consent and comply with the protocol.\n\nExclusion Criteria:\n\n* Healthy Volunteers (Stage I and II (Phase 1a and 1b)):\n\n  1. Subjects with any unresolved history of clinically significant disease, in the opinion of the investigator.\n  2. Past or intended use of over-the-counter (OTC) or prescription medication (other than ≤ 2 g\u002Fday paracetamol \\[acetaminophen\\] or ≤ 800-mg\u002Fday ibuprofen), vitamins, and dietary or herbal supplements within 7 days or 5 half-lives of the respective drug, if known (whichever is longer), prior to dosing.\n\n     Patients with Epilepsy (Stage II (Phase 1b)):\n  3. Acute precipitant of seizure within the past 3 months prior to screening such as major trauma, hypoglycemia, hyperglycemia, cardiac arrest, or post-anoxia\n\n     All Subjects:\n  4. Any uncontrolled medical or psychiatric condition (e.g., hypertension, diabetes, chronic obstructive pulmonary disorder, asthma, depression) as judged by the investigator.\n  5. Any clinically significant findings in medical examination, including physical examination, 12-lead ECG, vital signs, clinical laboratory tests. Specifically:\n\n     1. alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 × upper limit of normal (ULN), Total bilirubin ≥ 2 × ULN\n     2. QT interval corrected by Fridericia's formula (QTcF) \\> 450 msec (male) or \\> 470 msec (female)\n  6. Undergone major surgery ≤ 2 months prior to Day -1.\n  7. Received any investigational drug within 30 days or 5 half-lives (whichever is longer, if known) before screening.\n  8. Received any vaccine within 6 weeks before planned SIF001 administration.\n  9. Loss of more than 100 mL blood (e.g., a blood donation) within 2 months before Day -1, or has received any blood, plasma, or platelet transfusions within 3 months before admission.\n  10. Active liver disease or severe renal impairment, including serum creatinine ≥ 1.5 × ULN or estimated glomerular filtration rate of \\\u003C 60 mL\u002Fmin\u002F1.73m2.\n  11. Known history of substance use disorder.\n  12. History of active human immunodeficiency virus (HIV), active hepatitis C virus (HCV), or active hepatitis B virus (HBV)\n  13. Recent (2 weeks) history of a positive COVID-19 test result or disease symptoms of COVID-19 disease such as shortness of breath, cough, rhinorrhea, sore throat etc.\n  14. Known history of hypersensitivity or anaphylactic reaction to intravenous medications, biologicals, or fluids.\n  15. History of any clinically significant disease or disorder which, in the opinion of the investigators, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.\n  16. History of status epilepticus within 2 years of screening\n  17. Known history of suicidality within 2 years of screening, or answering \"yes\" to questions 4 and 5 of the Columbia Suicide Severity Rating Scale (C-SSRS)\n  18. Unable to complete this study for other reasons or the investigator believes that the subject should be excluded.","70 Years",{"count":517,"type":23},88,[54],"This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy",[29,521],"Healthy Volunteer",{"date":523,"type":36},"2026-06-15",{"date":525,"type":36},"2025-06-16",{"date":527,"type":23},"2027-03-15",{"name":529,"class":150},"Suninflam Inc",10,{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":245,"sex":18,"minAge":539,"maxAge":540,"enrollmentInfo":541,"targetDuration":4,"studyType":24,"phases":543,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":73},"100520133","healthy-aging-in-people-with-epilepsy-program-100520133","NCT06052605","Healthy Aging in People With Epilepsy Program","Healthy Aging in People With Epilepsy Program (HAP-E): Closing the Gap in Epilepsy Care","HAP-E","Inclusion Criteria:\n\n* Part 1a - Patient Survey:\n* Current diagnosis of epilepsy made by a neurologist, epileptologist, or internist\u002Ffamily medicine physician\n* Age 55 years or older\n* Proficiency in English (self-assessed)\n* Part 1b - Provider Survey:\n* Healthcare professional in the US who is involved in the clinical care or treatment of individuals with epilepsy (including Epilepsy Foundation organizational leaders)\n* Part 3:\n* Current diagnosis of epilepsy made by a neurologist, epileptologist, or internist\u002Ffamily medicine physician\n* Age 55 years or older (up to 90)\n* Proficiency in English (self-assessed)\n\nExclusion Criteria:\n\n* Part 1a:\n* Evidence of Dementia (based on phone cognitive screener; those with suspected mild cognitive impairment will not be excluded)\n* Age 90 years or older\n* Part 3:\n* Evidence of Dementia (based on phone cognitive screener; those with suspected mild cognitive impairment will not be excluded)\n* Age 90 years or older","55 Years","90 Years",{"count":542,"type":23},380,[26],"The goal of this clinical trial is to develop and test an educational program about dementia in older adults living with epilepsy. The main questions it aims to answer are:\n\n1. Can providing education on healthy aging, chronic disease management, dementia, and modifiable lifestyle dementia risk factors improve dementia knowledge and health literacy among older adults with epilepsy?\n2. Can aging related education and resources improve quality of life among older adults with epilepsy?\n\nParticipants will:\n\n* Be randomized to an intervention group or a control group.\n* Complete a 12-week group educational program (intervention group).\n* Complete pre- and post-program evaluation (intervention and control groups).",[29],"2026-06-10",{"date":478,"type":36},{"date":549,"type":36},"2026-03-25",{"date":551,"type":23},"2030-08-01",{"name":553,"class":43},"Anny Reyes",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":24,"phases":562,"briefSummary":564,"conditions":565,"keywords":567,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":73},"100601893","early-phase-1-effect-of-rose-odor-exposure-on-ictal-apnea-100601893","NCT07116421","Effect of Rose Odor Exposure on Ictal Apnea","Effect of 2-phenylethanol Odor Exposure on Ictal Apneic Episode Occurrence Rate in Patients With Epilepsy","Inclusion Criteria:\n\n* Adult epilepsy patients over the age of 18\n* Admission to the inpatient epilepsy monitoring unit (EMU) at Vanderbilt University Medical Center (VUMC)\n* Undergoing observational EEG monitoring without treatment involving seizure medication changes or other interventions for at least 48 hours\n\nExclusion Criteria:\n\n* Patients under the age of 18\n* Patients receiving EEG monitoring without interventions from baseline for less than 48 hours\n* Patients who are not receiving EEG monitoring as a part of their inpatient admission.",{"count":52,"type":23},[563],"EARLY_PHASE1","This study will investigate the potential benefits of rose scent in reducing the risk of Sudden Unexpected Death in Epilepsy (SUDEP) in patients with epilepsy. Participants will engage in their routine inpatient observational EEG monitoring for 24 hours followed by an additional 24 hours of observational EEG monitoring with continuous exposure to rose scent, during which an essential oil diffusor with rose scent will be placed in their hospital room. During these 48 total hours of the study, participants will wear a respiratory monitoring belt across their upper chest to measure their breathing.\n\nPotential risks include distress or discomfort when smelling the rose scent used in the study, a physical reaction to the rose scent, and discomfort or feelings of restrictiveness when wearing the respiratory monitoring belt. The total time commitment of the study is 48 consecutive hours over the course of the participants' inpatient EMU stay, during which there will be no restrictions on daily activities during the standard inpatient EMU admission except that participants must wear their respiratory belt for a majority of this 2-day period.",[29,566],"Sudden Unexpected Death in Epilepsy",[359,29,566],"2026-06-08",{"date":501,"type":36},{"date":571,"type":36},"2025-07-01",{"date":573,"type":23},"2027-05-08",{"name":575,"class":43},"Vanderbilt University Medical Center",{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":18,"minAge":583,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":24,"phases":586,"briefSummary":587,"conditions":588,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":596},"100587897","subcortical-arousal-in-perceptual-awareness-100587897","NCT06934356","Subcortical Arousal in Perceptual Awareness","Shared Subcortical Arousal Systems Across Perceptual Modalities","A. The following are the inclusion\u002Fexclusion criteria for healthy participants age 18 years and up (Aim 1 and 2):\n\nInclusion: (1) normal vision with or without the use of corrective lenses; (2) normal hearing not needing an assistive hearing device.\n\nExclusion: (1) past history of diagnosis of a psychiatric or neurologic disease; (2) current psychiatric or neurologic disease; (3) requires hard contact lenses or glasses to maintain normal vision (prevents accurate pupil and eye gaze measurements); (4) pregnant or nonremovable ferrous metal objects inside or on the body (prevents MRI).\n\nB. The following are the inclusion\u002Fexclusion criteria for epilepsy patients with thalamic electrodes age 13 years and up (Aim 3A):\n\nInclusion: (1) normal vision with or without the use of corrective lenses\n\nExclusion: (1) severe vision impairment even with correction preventing ability to see stimuli (prevents accurate pupil and eye gaze measurements); (2) unable to perform the perception task due to cognitive impairment. All participants must be capable of consenting for themselves.\n\nC. The following are the inclusion\u002Fexclusion criteria for epilepsy patients with thalamic electrodes age 18 year and up (Aim 3B):\n\nInclusion: (1) normal vision with or without the use of corrective lenses; (2) A female subject must have a negative pregnancy test and if sexually active, must be using a reliable form of birth control for the duration of the trial, be surgically sterile, or be at least two years post-menopausal.\n\nExclusion: (1) severe vision impairment even with correction preventing ability to see stimuli (prevents accurate pupil and eye gaze measurements); (2) unable to perform the perception task due to cognitive impairment. All participants must be capable of consenting for themselves; (3) Pregnancy.","13 Years",{"count":585,"type":23},202,[26],"The study consists of prospective enrollment of healthy participants and patients with epilepsy, as well as analysis of an existing data set. Healthy participants will be studied with fMRI, eye metrics and behavioral testing at Yale. Patients will be studied with intracranial thalamic and cortical recording and stimulation, eye metrics and behavioral testing.",[29],{"date":546,"type":36},{"date":591,"type":36},"2025-10-13",{"date":593,"type":23},"2030-12",{"name":595,"class":43},"Yale University",8,{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":18,"minAge":603,"maxAge":604,"enrollmentInfo":605,"targetDuration":4,"studyType":24,"phases":606,"briefSummary":607,"conditions":608,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":611,"completionDateStruct":612,"leadSponsor":614,"locationsCount":73},"100566944","clinic-based-and-technology-supported-sleep-intervention-for-pediatric-epilepsy-100566944","NCT06661759","Clinic-based and Technology-Supported Sleep Intervention for Pediatric Epilepsy","Inclusion Criteria:\n\n* Children aged between 1.5 and 9 years with a confirmed diagnosis of epilepsy.\n* Parents with sufficient Chinese language skills to fully comprehend the trial and complete questionnaires.\n\nExclusion Criteria:\n\n* Children who are bedridden.\n* Children with a documented sleep disorder, such as obstructive or central sleep apnea and sleep-related movement disorders\n* Children born with a congenital, genetic, or orthopedic abnormality that limit their activities of daily living or impair their physical activity.","18 Months","9 Years",{"count":218,"type":23},[26],"Sleep problems are more common and more severe in children with epilepsy. The purpose of this study is to develop and evaluate the effect of a clinic-based and technology-supported sleep intervention for improving sleep and health in children with epilepsy and their parents.",[29],"2026-06-07",{"date":546,"type":36},{"date":67,"type":36},{"date":613,"type":23},"2027-12-31",{"name":615,"class":43},"National Taiwan University Hospital"]